Takeda mulls Shire divestments to fund acquisition - Bloomberg

14 September 2018

Japan's Takeda Pharmaceutical (TYO: 4502) is considering selling the ophthalmics division of Shire (LSE: SHP) directly after buying the rare disease specialist, according to a report from Bloomberg.

After around a month of discussion and several offers, Shire finally agreed to a £46 billion ($64 billion) takeover bid from Takeda earlier this year.

The move raised concerns among a small group of Takeda shareholders about the size of the acquisition and the level of debt required to complete the deal.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK